FDA Approves Emrosi for Rosacea in Adults
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 12, 2024 -- The U.S. Food and Drug Administration has approved Emrosi (minocycline hydrochloride) for the treatment of inflammatory rosacea in adults.
The extended-release capsules (40 mg) will be available late in the first quarter or early in the second quarter of 2025.
The approval was based on positive results from two 16-week phase 3 clinical trials, during which Emrosi met all coprimary and secondary end points and showed significant superiority over both the current standard-of-care treatment (Oracea) and placebo for Investigator’s Global Assessment treatment success as well as reduction in total inflammatory lesion count. Additionally, participants experienced no significant safety issues.
"Rosacea is a difficult to treat skin condition, and based on the favorable results from our phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition," Claude Maraoui, the cofounder, president, and CEO of Journey Medical, said in a statement. "Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea."
The approval of Emrosi was granted to Journey Medical.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
At-Home Light-Emitting Diode Devices Safe, Effective for Acne Treatment
THURSDAY, March 6, 2025 -- At-home light-emitting diode (LED) devices are effective for treating acne, according to a research letter published online March 5 in JAMA...
Direct CGRP Inhibition Cuts Acne, Rosacea in Patients With Migraine
TUESDAY, July 16, 2024 -- For patients experiencing migraine, direct calcitonin gene-related peptide (CGRP) inhibition with monoclonal antibodies (mAbs) is associated with reduced...
Isotretinoin Effective for Acne in Those Receiving Gender-Affirming Therapy
FRIDAY, June 7, 2024 -- Isotretinoin is well tolerated and effective for individuals receiving masculinizing gender-affirming hormonal therapy who have acne, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.